- Adjusted free cash flow was $2.5 billion for the year, $500 million above expectations.
- Cardinal Health grew operating earnings by 19% in Q4 and 15% for fiscal year 2025, with EPS growth of 13% in Q4 and over 9% for the year.
- Fiscal year 2025 revenue decreased 2% to $223 billion due to contract expiration but increased 18% excluding it; operating earnings grew 15% to $2.8 billion.
- GMPD segment revenue grew 3% to $3.2 billion with a record Q4 segment profit of $70 million.
- Gross profit grew 17% to $2.2 billion in Q4, with a 50 basis point improvement in rate due to favorable product, customer, and business mix.
- Other growth businesses saw 37% revenue growth to $1.6 billion and 44% profit growth to $160 million in Q4.
- Pharma segment revenue was flat at $55.4 billion in Q4 but increased 22% excluding contract expiration; segment profit grew 11% to $535 million.
- SG&A increased 16% to $1.5 billion in Q4, primarily due to acquisitions; on an organic basis, SG&A grew 4%.
- Total company revenue was flat at $60.2 billion in Q4, but adjusted for a customer contract expiration, revenue increased 21%.
Related items and other data are not available for this feed item.
Dafinchi